# FDA Approves Generic Dapagliflozin from Macleods Pharmaceuticals The U.S. FDA has approved Macleods Pharmaceuticals Limited's generic version of dapagliflozin, an SGLT2 inhibitor widely used to treat type 2 diabetes and heart failure, potentially intensifying price competition in a market currently dominated by branded competitors. The approval is expected to expand patient access to the medication and provide healthcare providers and payers with more cost-effective treatment options.